OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections
Display Omitted
Gespeichert in:
| Autor*in: |
Galhano, Joana [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2022 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS - Vidoni, Eric D. ELSEVIER, 2019, an international journal, San Diego, Calif |
|---|---|
| Übergeordnetes Werk: |
volume:118 ; year:2022 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1016/j.bioorg.2021.105470 |
|---|
| Katalog-ID: |
ELV056061935 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | ELV056061935 | ||
| 003 | DE-627 | ||
| 005 | 20230624225330.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220105s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bioorg.2021.105470 |2 doi | |
| 028 | 5 | 2 | |a /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica |
| 035 | |a (DE-627)ELV056061935 | ||
| 035 | |a (ELSEVIER)S0045-2068(21)00848-8 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.68 |2 bkl | ||
| 100 | 1 | |a Galhano, Joana |e verfasserin |4 aut | |
| 245 | 1 | 9 | |a OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections |
| 264 | 1 | |c 2022 | |
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a Display Omitted | ||
| 650 | 7 | |a Mesoporous silica nanoparticles |2 Elsevier | |
| 650 | 7 | |a Drug delivery |2 Elsevier | |
| 650 | 7 | |a Synergistic effect |2 Elsevier | |
| 650 | 7 | |a Antimicrobial resistance |2 Elsevier | |
| 650 | 7 | |a Epirubicin |2 Elsevier | |
| 650 | 7 | |a Ofloxacin |2 Elsevier | |
| 650 | 7 | |a Doxorubicin |2 Elsevier | |
| 700 | 1 | |a Marcelo, Gonçalo A. |4 oth | |
| 700 | 1 | |a Duarte, Maria Paula |4 oth | |
| 700 | 1 | |a Oliveira, Elisabete |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |n Elsevier |a Vidoni, Eric D. ELSEVIER |t TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS |d 2019 |d an international journal |g San Diego, Calif |w (DE-627)ELV003009882 |
| 773 | 1 | 8 | |g volume:118 |g year:2022 |g pages:0 |
| 856 | 4 | 0 | |u https://doi.org/10.1016/j.bioorg.2021.105470 |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ELV | ||
| 912 | |a SYSFLAG_U | ||
| 936 | b | k | |a 44.68 |j Gerontologie |j Geriatrie |q VZ |
| 951 | |a AR | ||
| 952 | |d 118 |j 2022 |h 0 | ||
| author_variant |
j g jg |
|---|---|
| matchkey_str |
galhanojoanamarcelogonaloaduartemariapau:2022----:foaidxrbcnprbcnucinlzdc4mspruslcbsdaoaressyegsidudlvrt |
| hierarchy_sort_str |
2022 |
| bklnumber |
44.68 |
| publishDate |
2022 |
| allfields |
10.1016/j.bioorg.2021.105470 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica (DE-627)ELV056061935 (ELSEVIER)S0045-2068(21)00848-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.68 bkl Galhano, Joana verfasserin aut OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin Elsevier Marcelo, Gonçalo A. oth Duarte, Maria Paula oth Oliveira, Elisabete oth Enthalten in Elsevier Vidoni, Eric D. ELSEVIER TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS 2019 an international journal San Diego, Calif (DE-627)ELV003009882 volume:118 year:2022 pages:0 https://doi.org/10.1016/j.bioorg.2021.105470 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 118 2022 0 |
| spelling |
10.1016/j.bioorg.2021.105470 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica (DE-627)ELV056061935 (ELSEVIER)S0045-2068(21)00848-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.68 bkl Galhano, Joana verfasserin aut OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin Elsevier Marcelo, Gonçalo A. oth Duarte, Maria Paula oth Oliveira, Elisabete oth Enthalten in Elsevier Vidoni, Eric D. ELSEVIER TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS 2019 an international journal San Diego, Calif (DE-627)ELV003009882 volume:118 year:2022 pages:0 https://doi.org/10.1016/j.bioorg.2021.105470 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 118 2022 0 |
| allfields_unstemmed |
10.1016/j.bioorg.2021.105470 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica (DE-627)ELV056061935 (ELSEVIER)S0045-2068(21)00848-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.68 bkl Galhano, Joana verfasserin aut OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin Elsevier Marcelo, Gonçalo A. oth Duarte, Maria Paula oth Oliveira, Elisabete oth Enthalten in Elsevier Vidoni, Eric D. ELSEVIER TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS 2019 an international journal San Diego, Calif (DE-627)ELV003009882 volume:118 year:2022 pages:0 https://doi.org/10.1016/j.bioorg.2021.105470 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 118 2022 0 |
| allfieldsGer |
10.1016/j.bioorg.2021.105470 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica (DE-627)ELV056061935 (ELSEVIER)S0045-2068(21)00848-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.68 bkl Galhano, Joana verfasserin aut OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin Elsevier Marcelo, Gonçalo A. oth Duarte, Maria Paula oth Oliveira, Elisabete oth Enthalten in Elsevier Vidoni, Eric D. ELSEVIER TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS 2019 an international journal San Diego, Calif (DE-627)ELV003009882 volume:118 year:2022 pages:0 https://doi.org/10.1016/j.bioorg.2021.105470 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 118 2022 0 |
| allfieldsSound |
10.1016/j.bioorg.2021.105470 doi /cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica (DE-627)ELV056061935 (ELSEVIER)S0045-2068(21)00848-8 DE-627 ger DE-627 rakwb eng 610 VZ 44.68 bkl Galhano, Joana verfasserin aut OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections 2022 nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier Display Omitted Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin Elsevier Marcelo, Gonçalo A. oth Duarte, Maria Paula oth Oliveira, Elisabete oth Enthalten in Elsevier Vidoni, Eric D. ELSEVIER TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS 2019 an international journal San Diego, Calif (DE-627)ELV003009882 volume:118 year:2022 pages:0 https://doi.org/10.1016/j.bioorg.2021.105470 Volltext GBV_USEFLAG_U GBV_ELV SYSFLAG_U 44.68 Gerontologie Geriatrie VZ AR 118 2022 0 |
| language |
English |
| source |
Enthalten in TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS San Diego, Calif volume:118 year:2022 pages:0 |
| sourceStr |
Enthalten in TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS San Diego, Calif volume:118 year:2022 pages:0 |
| format_phy_str_mv |
Article |
| bklname |
Gerontologie Geriatrie |
| institution |
findex.gbv.de |
| topic_facet |
Mesoporous silica nanoparticles Drug delivery Synergistic effect Antimicrobial resistance Epirubicin Ofloxacin Doxorubicin |
| dewey-raw |
610 |
| isfreeaccess_bool |
false |
| container_title |
TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS |
| authorswithroles_txt_mv |
Galhano, Joana @@aut@@ Marcelo, Gonçalo A. @@oth@@ Duarte, Maria Paula @@oth@@ Oliveira, Elisabete @@oth@@ |
| publishDateDaySort_date |
2022-01-01T00:00:00Z |
| hierarchy_top_id |
ELV003009882 |
| dewey-sort |
3610 |
| id |
ELV056061935 |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056061935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624225330.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bioorg.2021.105470</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056061935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0045-2068(21)00848-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Galhano, Joana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="9"><subfield code="a">OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Display Omitted</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mesoporous silica nanoparticles</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug delivery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Synergistic effect</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antimicrobial resistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epirubicin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ofloxacin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Doxorubicin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marcelo, Gonçalo A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duarte, Maria Paula</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oliveira, Elisabete</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Vidoni, Eric D. ELSEVIER</subfield><subfield code="t">TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS</subfield><subfield code="d">2019</subfield><subfield code="d">an international journal</subfield><subfield code="g">San Diego, Calif</subfield><subfield code="w">(DE-627)ELV003009882</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:118</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bioorg.2021.105470</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.68</subfield><subfield code="j">Gerontologie</subfield><subfield code="j">Geriatrie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">118</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| author |
Galhano, Joana |
| spellingShingle |
Galhano, Joana ddc 610 bkl 44.68 Elsevier Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections |
| authorStr |
Galhano, Joana |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)ELV003009882 |
| format |
electronic Article |
| dewey-ones |
610 - Medicine & health |
| delete_txt_mv |
keep |
| author_role |
aut |
| collection |
elsevier |
| remote_str |
true |
| illustrated |
Not Illustrated |
| topic_title |
610 VZ 44.68 bkl OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin Elsevier |
| topic |
ddc 610 bkl 44.68 Elsevier Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin |
| topic_unstemmed |
ddc 610 bkl 44.68 Elsevier Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin |
| topic_browse |
ddc 610 bkl 44.68 Elsevier Mesoporous silica nanoparticles Elsevier Drug delivery Elsevier Synergistic effect Elsevier Antimicrobial resistance Elsevier Epirubicin Elsevier Ofloxacin Elsevier Doxorubicin |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| author2_variant |
g a m ga gam m p d mp mpd e o eo |
| hierarchy_parent_title |
TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS |
| hierarchy_parent_id |
ELV003009882 |
| dewey-tens |
610 - Medicine & health |
| hierarchy_top_title |
TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)ELV003009882 |
| title |
OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections |
| ctrlnum |
(DE-627)ELV056061935 (ELSEVIER)S0045-2068(21)00848-8 |
| title_full |
OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections |
| author_sort |
Galhano, Joana |
| journal |
TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS |
| journalStr |
TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS |
| lang_code |
eng |
| isOA_bool |
false |
| dewey-hundreds |
600 - Technology |
| recordtype |
marc |
| publishDateSort |
2022 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
Galhano, Joana |
| container_volume |
118 |
| class |
610 VZ 44.68 bkl |
| format_se |
Elektronische Aufsätze |
| author-letter |
Galhano, Joana |
| doi_str_mv |
10.1016/j.bioorg.2021.105470 |
| dewey-full |
610 |
| title_sort |
doxorubicin-epirubicin functionalized mcm-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections |
| title_auth |
OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections |
| abstract |
Display Omitted |
| abstractGer |
Display Omitted |
| abstract_unstemmed |
Display Omitted |
| collection_details |
GBV_USEFLAG_U GBV_ELV SYSFLAG_U |
| title_short |
OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections |
| url |
https://doi.org/10.1016/j.bioorg.2021.105470 |
| remote_bool |
true |
| author2 |
Marcelo, Gonçalo A. Duarte, Maria Paula Oliveira, Elisabete |
| author2Str |
Marcelo, Gonçalo A. Duarte, Maria Paula Oliveira, Elisabete |
| ppnlink |
ELV003009882 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| author2_role |
oth oth oth |
| doi_str |
10.1016/j.bioorg.2021.105470 |
| up_date |
2024-07-06T19:19:32.114Z |
| _version_ |
1803858552673009664 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">ELV056061935</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230624225330.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">220105s2022 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1016/j.bioorg.2021.105470</subfield><subfield code="2">doi</subfield></datafield><datafield tag="028" ind1="5" ind2="2"><subfield code="a">/cbs_pica/cbs_olc/import_discovery/elsevier/einzuspielen/GBV00000000001857.pica</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)ELV056061935</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(ELSEVIER)S0045-2068(21)00848-8</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">610</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="084" ind1=" " ind2=" "><subfield code="a">44.68</subfield><subfield code="2">bkl</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Galhano, Joana</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="9"><subfield code="a">OfloxacinDoxorubicin-Epirubicin functionalized MCM-41 mesoporous silica–based nanocarriers as synergistic drug delivery tools for cancer related bacterial infections</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2022</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Display Omitted</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Mesoporous silica nanoparticles</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Drug delivery</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Synergistic effect</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Antimicrobial resistance</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Epirubicin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Ofloxacin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="650" ind1=" " ind2="7"><subfield code="a">Doxorubicin</subfield><subfield code="2">Elsevier</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Marcelo, Gonçalo A.</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Duarte, Maria Paula</subfield><subfield code="4">oth</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Oliveira, Elisabete</subfield><subfield code="4">oth</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="n">Elsevier</subfield><subfield code="a">Vidoni, Eric D. ELSEVIER</subfield><subfield code="t">TRIAL OF OXALOACETATE IN ALZHEIMER’S DISEASE (TOAD): FINAL RESULTS</subfield><subfield code="d">2019</subfield><subfield code="d">an international journal</subfield><subfield code="g">San Diego, Calif</subfield><subfield code="w">(DE-627)ELV003009882</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:118</subfield><subfield code="g">year:2022</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.1016/j.bioorg.2021.105470</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ELV</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_U</subfield></datafield><datafield tag="936" ind1="b" ind2="k"><subfield code="a">44.68</subfield><subfield code="j">Gerontologie</subfield><subfield code="j">Geriatrie</subfield><subfield code="q">VZ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">118</subfield><subfield code="j">2022</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.4006224 |